UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000025880
Receipt number R000029753
Scientific Title Long term Phase 3 Open clinical trial of sodium pyruvate on lactic acidosis associated with mitochondrial disorders (Leigh syndrome)
Date of disclosure of the study information 2017/01/30
Last modified on 2019/01/28 10:32:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Long term Phase 3 Open clinical trial of sodium pyruvate on lactic acidosis associated with mitochondrial disorders (Leigh syndrome)

Acronym

Long term Phase 3 Open clinical trial of sodium pyruvate on lactic acidosis associated with mitochondrial disorders (Leigh syndrome)

Scientific Title

Long term Phase 3 Open clinical trial of sodium pyruvate on lactic acidosis associated with mitochondrial disorders (Leigh syndrome)

Scientific Title:Acronym

Long term Phase 3 Open clinical trial of sodium pyruvate on lactic acidosis associated with mitochondrial disorders (Leigh syndrome)

Region

Japan


Condition

Condition

Leigh disorders

Classification by specialty

Medicine in general Neurology Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the long term (48W) efficacy and safety of sodium pyruvate on Leigh disorders

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase III


Assessment

Primary outcomes

Safety
Total score of section 1 -3, 4 in NMDAS at 48 weeks after oral administration
Change of section 1-3,4 at 48 weeks after oral administration
Change of the score of section 1, 2, 3, 4 in NMDPS.
GDF15
emergency visit
lactate
lactate in proton MRS
mortality
period of in-patient during clinical trial

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

sodium pyruvate 0.5g/kg/day TID 48 weeks. We can use sodium pyruvate up to 2.0g/kg/day TID.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

2 years-old <

Age-upper limit

30 years-old >

Gender

Male and Female

Key inclusion criteria

Leigh disease who fulfilled the following criteria
1)neurological findings (all matched)
progressive central neurological sings
symptoms suggesting bilateral brain stem abnormality
bilateral necrosis of brain stem by MRI
2)defined mitochondrial dysfunction (one of the following )
by repeated abnormality of serum lactate
by respiratory chain enzyme activity
by muscle pathology
by genetic abnormality

Key exclusion criteria

1) patients who is not evaluated by this protocol of the clinical trial
2)severe unconsciousness
3)sepsis
4)renal dysfunction by eGFR lower than 60 mL/min/1.73m2
5)heart failure (EF<40%)
6)status epileptics
7)pregnant
8)allergy against the sodium pyruvate
9)enrolled to the other clinical trial 24 weeks before this trial
10)patient who cannot evaluate the muscle activity by device
11)patients who are not recommended by the doctor

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasutoshi Koga

Organization

Kurume University

Division name

Department of Pediatrics and Child Health

Zip code


Address

67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan

TEL

0942-31-7565

Email

yasukoga@med.kurume-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yasutoshi Koga

Organization

Kurume University

Division name

Department of Pediatrics and Child Health

Zip code


Address

67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan

TEL

0942-31-7565

Homepage URL

http://www.ped-kurume.com/

Email

yasukoga@med.kurume-u.ac.jp


Sponsor or person

Institute

Japan Agency of Medical Research and Development

Institute

Department

Personal name



Funding Source

Organization

Japan Agency of Medical Research and Development

Organization

Division

Category of Funding Organization

Government offices of other countries

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

久留米大学病院(福岡県)、筑波大学病院(茨城県)、千葉大学病院(千葉県)、千葉県立こども病院(千葉県)、名古屋市立大学病院(愛知県)、大阪府立母子保健総合医療センター(大阪府)、信州大学病院(長野県)


Other administrative information

Date of disclosure of the study information

2017 Year 01 Month 30 Day


Related information

URL releasing protocol

https://www.c-ctd.co.jp/project_PLA003/index.html

Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results

Unfortunately, data obtained by the clinical trials could not prove the efficacy overall, though there are several patients with perfect improvement by clinical rating scales. After the strategy consultation to PMDA on October 18, 2018, we decided to terminate the SP project.

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2017 Year 01 Month 16 Day

Date of IRB


Anticipated trial start date

2018 Year 02 Month 01 Day

Last follow-up date

2019 Year 02 Month 28 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 01 Month 27 Day

Last modified on

2019 Year 01 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029753


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name